Russell Investments Group Ltd. Acquires 45,892 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Russell Investments Group Ltd. boosted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 18.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 298,662 shares of the company’s stock after acquiring an additional 45,892 shares during the quarter. Russell Investments Group Ltd.’s holdings in Kura Oncology were worth $2,601,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in KURA. Harbor Advisors LLC bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology during the 4th quarter worth $90,000. Corient Private Wealth LLC bought a new stake in shares of Kura Oncology in the 4th quarter worth $109,000. Teacher Retirement System of Texas raised its holdings in shares of Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Kura Oncology during the fourth quarter valued at about $127,000.

Kura Oncology Trading Up 2.6 %

Shares of Kura Oncology stock opened at $5.90 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The firm has a market cap of $476.59 million, a PE ratio of -2.50 and a beta of 0.83. The company has a 50 day simple moving average of $7.18 and a two-hundred day simple moving average of $10.64.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 in the last quarter. 5.50% of the stock is owned by insiders.

Analyst Ratings Changes

KURA has been the topic of several recent analyst reports. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. JMP Securities reissued a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.